The development of small molecule serine-threonine kinase inhibitors (vemurafenib and dabrafenib) that specifically target mutant BRAF has revolutionized the treatment of melanoma, and clinical trials are underway for treatment of pediatric gliomas carrying the BRAFV600E mutation (NCT01748149, NCT02034110). This evidence concerns the gene BRAF and melanoma.